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Lystra P. Hayden1,2*, Brian D. Hobbs2,3, Robyn T. Cohen4, Robert A. Wise5, William Checkley5, James D. Crapo6,
Craig P. Hersh2,3 and on behalf of the COPDGene InvestigatorsAbstract
Background: Development of adult respiratory disease is influenced by events in childhood. The impact of
childhood pneumonia on chronic obstructive pulmonary disease (COPD) is not well defined. We hypothesize that
childhood pneumonia is a risk factor for reduced lung function and COPD in adult smokers.
Methods: COPD cases and control smokers between 45–80 years old from the United States COPDGene Study
were included. Childhood pneumonia was defined by self-report of pneumonia at <16 years. Subjects with lung
disease other than COPD or asthma were excluded. Smokers with and without childhood pneumonia were
compared on measures of respiratory disease, lung function, and quantitative analysis of chest CT scans.
Results: Of 10,192 adult smokers, 854 (8.4 %) reported pneumonia in childhood. Childhood pneumonia was
associated with COPD (OR 1.40; 95 % CI 1.17-1.66), chronic bronchitis, increased COPD exacerbations, and lower
lung function: post-bronchodilator FEV1 (69.1 vs. 77.1 % predicted), FVC (82.7 vs. 87.4 % predicted), FEV1/FVC
ratio (0.63 vs. 0.67; p < 0.001 for all comparisons). Childhood pneumonia was associated with increased airway
wall thickness on CT, without significant difference in emphysema. Having both pneumonia and asthma in
childhood further increased the risk of developing COPD (OR 1.85; 95 % CI 1.10-3.18).
Conclusions: Children with pneumonia are at increased risk for future smoking-related lung disease including
COPD and decreased lung function. This association is supported by airway changes on chest CT scans.
Childhood pneumonia may be an important factor in the early origins of COPD, and the combination of
pneumonia and asthma in childhood may pose the greatest risk.
Clinical trials registration: ClinicalTrials.gov, NCT00608764 (Active since January 28, 2008).Background
Pneumonia is a common pediatric diagnosis that poses a
significant risk for future respiratory disease [1, 2]. Mul-
tiple investigations have found an association between
pneumonia in childhood and decreased adult lung func-
tion, raising the question of whether childhood pneumonia
is a risk factor for chronic obstructive pulmonary disease
(COPD). Prior studies are limited by small sample sizes,* Correspondence: Lystra.Hayden@childrens.harvard.edu
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function, differing definitions of respiratory illness, sam-
pling bias, and recall bias [3–10]. This study examines the
effect of childhood pneumonia in a large population of
older adults, including objective diagnosis of COPD with
standardized post-bronchodilator spirometry and analysis
of chest computed tomography (CT).
Smoking remains a major risk for children, with one in
fifteen high school seniors reporting daily cigarette use
[11]. Most smokers initiate the habit by age 18, putting
them at risk for a wide range of comorbidities including
COPD [12]. Recently, there has been interest in the early
origins of COPD and the potential synergistic relationship
between childhood respiratory infection, aberrant lunge is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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lated injury [10, 13–15]. More data is needed to guide pro-
viders in anticipating the outcomes of childhood
pneumonia and potential additional complications from
smoking.
This study examines the association between pneumo-
nia in childhood and future respiratory illness in
smokers. We hypothesize that childhood pneumonia is a
risk factor for reduced lung function and COPD in adult
smokers. Some of the results have been published previ-
ously as an abstract [16].
Materials and methods
Subjects
We evaluated 10,192 current and former United States
smokers with and without COPD from the COPDGene
Study, a multicenter, observational study designed to iden-
tify genetic and environmental factors associated with
COPD. COPDGene enrolled subjects from 2008–2011.
It was approved by the Institutional Review Boards at
each of the twenty-one clinical sites. All participants
provided written informed consent [17]. Subjects were
45–80 years of age, non-Hispanic white or African
American, and had at least a 10 pack-year smoking
history. Exclusion criteria included history of lung
disease other than COPD or asthma (e.g. extensive
bronchiectasis, cystic fibrosis, pulmonary fibrosis, lung
cancer). Study protocol, enrollment criteria, and data
collection forms were previously described and are
available at www.copdgene.org [17, 18].
Data collection
Participants completed a modified American Thoracic So-
ciety Respiratory Epidemiology Questionnaire, Modified
Medical Research Council (MMRC) dyspnea scale, and
questionnaires related to demographics and medical history
[18–20]. Quality of life was assessed using the St. George’s
Respiratory Questionnaire (SGRQ) [21]. Subjects com-
pleted a standardized spirometry protocol (ndd EasyOne
Spirometer, Zurich, Switzerland). Inspiratory and expiratory
chest CT scans were obtained. Airway measurements,
performed using VIDA software (VIDA Diagnostics;
Iowa City, Iowa), assessed wall thickening in segmental
airways, subsegmental airways, and the square root of
the wall area of a hypothetical airway with 10mm
internal perimeter (SRWA-Pi10) [22, 23]. SLICER soft-
ware (www.slicer.org) was used to quantify emphysema
by inspiratory scan low-attenuation areas < -950 Hounsfield
units (HU) and gas trapping on expiratory scan at < -856
HU [24].
Case identification
Childhood pneumonia was defined by subject self-
report. The questionnaire asked: “Have you ever hadpneumonia or bronchopneumonia?” and their age at the
first episode. Subjects were classified as childhood pneu-
monia if they reported an age of first pneumonia at < 16
years or “As a child; age not known.” Subjects were clas-
sified as no childhood pneumonia if they reported no
pneumonias, an age of first pneumonia ≥ 16 years, or if
they did not indicated their first pneumonia was during
childhood. Age sixteen was used to define pediatric
pneumonia as this was when most subjects in the cohort
started smoking (mean 16.9, standard deviation 4.6
years), which is concurrent with a rise in subjects report-
ing a first episode of pneumonia between ages 15-20.
Chronic bronchitis was defined by cough and phlegm
production lasting more than three months per year for
at least two years. COPD exacerbations were defined by
use of antibiotics or systemic steroids. Severe COPD ex-
acerbations required an emergency room visit or
hospitalization. Cardiovascular disease (CVD) was de-
fined by self-reported history of coronary artery disease,
congestive heart failure, heart attack (MI), angioplasty,
coronary artery bypass graft surgery, peripheral vascular
disease, transient ischemic attack, or stroke [25]. Child-
hood asthma was defined as reported history of asthma
diagnosed by a health professional with age of onset at <
16. COPD was defined based on post-bronchodilator
forced expiratory volume in the first second (FEV1) to
forced vital capacity (FVC) ratio < 0.7 with FEV1 < 80 %
predicted, corresponding to Global Initiative for Chronic
Obstructive Lung Disease (GOLD) Stages 2-4 [26]. Con-
trol smokers had normal spirometry, defined as FEV1/
FVC ≥ 0.7 and FEV1 ≥ 80 %.
Statistical analysis
Subjects with and without childhood pneumonia were
compared by demographics, respiratory symptoms/dis-
eases, lung function, and CT measurements. Statistical
analysis was performed using R v3.1.1. Single variable
analysis used chi-square tests, t-tests, or Wilcoxon rank
sum tests. Multivariable regression analysis was per-
formed, with most models adjusted for standard covari-
ates of age, gender, race and smoking history. Additional
covariates of FEV1 % predicted, height, body mass index,
and CT scanner model were included for some analyses.
Logistic regression reported odds ratios (OR) with 95 %
confidence intervals (CI) and linear regression reported
absolute differences (β) with standard errors (SE). Sub-
jects with missing or unclassifiable responses were re-
moved from specific analyses.
Regression analysis was repeated in three subsets.
First, to assess the effect of asthma, the analysis was
performed on subjects without childhood asthma. Sec-
ond, the analysis was run on only subjects with child-
hood asthma. Finally, to assess the effect of recall bias,
Hayden et al. Respiratory Research  (2015) 16:115 Page 3 of 9spirometry was analyzed in subjects who did not report
a history of COPD or emphysema.
Results
Subject classification and characteristics
COPDGene includes 10,192 current and former
smokers (Additional file 1: Figure S1). Thirty-six sub-
jects were excluded, as it was not possible to classify
their pneumonia history by questionnaire response.
Of the 10,156 subjects included, 854 (8.4 %) reported
childhood pneumonia. Of these, 405 subjects had
COPD and 282 had normal spirometry. Of the 9,302
subjects without childhood pneumonia, 3,267 had
COPD, and 4,097 had normal spirometry. Subjects
with GOLD Stage 1 spirometry (FEV1/FVC < 0.7 with
FEV1 ≥ 80 % predicted) or subjects with Preserved
Ratio Impaired Spirometry (PRISm, FEV1/FVC ≥ 0.7
with FEV1 < 80 % predicted) were not included in
COPD analysis; they were included in the other as-
sessments [27].
Subjects with childhood pneumonia were older and
more likely to be non-Hispanic white (Table 1). They
were more likely to report living with a smoker in child-
hood, having a greater lifetime smoking intensity, were
less likely to be current smokers, and had an increased
number of lifetime pneumonia episodes. The distribu-
tion of age of first pneumonia can be seen in Additional
file 1: Figure S2.Table 1 Characteristics of Subjects With and Without History of Chil
Childhood
N = 854 (8.
DEMOGRAPHIC
Male gender (%) 437
Mean age, years (SD) 61.7
Non-Hispanic white (%) 693
SMOKE EXPOSURE
In-utero smoke exposure (%)a 206
Lived with smoker in childhood (%)a 732
Mean age started smoking, years (SD) 16.5
Pack-years of smoking (SD) 49.8
Current smoking (%) 379
PNEUMONIA HISTORY
Ever had pneumonia (%) 854
Diagnosed with pneumonia by healthcare provider (%)a 821
Pneumonia childhood age unknown (%) 378
Age first pneumonia in years, mean (SD)a 7.7
Lifetime pneumonia episodes (SD)a 3.9
Abbreviations: SD standard deviation
aSubjects included are fewer than total subjects due to subject survey response bei
bUnivariate analysis with chi-square or Wilcoxon rank sum test unless otherwise speRespiratory symptoms and disease
Smokers with childhood pneumonia were more likely
to develop COPD (Table 2). This remained robust
when childhood asthma was added to the model.
Childhood pneumonia was associated with increased
chronic bronchitis, more frequent and severe COPD
exacerbations in the year prior and increased fre-
quency of co-morbid CVD (Table 3). These subjects
were more likely to report asthma diagnosed by a
healthcare provider and asthma onset in childhood.
Childhood pneumonia was associated with worse
disease-related quality of life with higher SGRQ, and
more severe dyspnea with higher MMRC.
Spirometry showed post-bronchodilator FEV1 % pre-
dicted, FVC % predicted and FEV1/FVC were all signifi-
cantly lower in subjects with childhood pneumonia
(Fig. 1, Table 4). In regression analysis, chest CT pa-
rameters related to airways disease were significantly
increased in subjects with childhood pneumonia, with
greater airway wall thickness in segmental and subseg-
mental airways and greater SRWA-Pi10 (Fig. 2, Table 5
and in the Additional file 1: Table S1). These subjects
also had increased gas trapping. Multivariable analysis
showed no difference in emphysema or total lung cap-
acity measured by chest CT.
Sensitivity and recall analyses
To assess the effect of asthma, regression analysis was
repeated in a subset of 9,405 subjects, excluding 723dhood Pneumonia
Pneumonia No Childhood Pneumonia p Valueb
4 %) N = 9302 (91.6 %)
(51.2 %) 4990 (53.6 %) 0.18
(8.9) 59.4 (9.0) <0.001c
(81.1 %) 6073 (65.3 %) <0.001
(33.0 %) 2082 (30.2 %) 0.18
(85.7 %) 7618 (81.9 %) 0.006
(4.4) 16.9 (4.7) 0.06
(28.4) 43.7 (24.6) <0.001
(44.4 %) 5011 (53.9 %) <0.001
(100.0 %) 2979 (33.9 %) <0.001
(96.1 %) 2920 (31.4 %) <0.001
(44.3 %) 0 (0.0 %) <0.001
(4.5) 42.5 (15.6) <0.001
(4.9) 2.5 (3.0) <0.001
ng missing or unclassifiable
cifiedc t test
Table 2 COPD in Subjects With and Without History of Childhood Pneumonia
Childhood Pneumonia No Childhood Pneumonia Impact of Childhood Pneumoniaa
N = 687 (8.5 %) N = 7364 (91.5 %) OR (95 % CI) p Valueb
COPD, GOLD 2-4 405 (59.0 %) 3267 (44.4 %) 1.40 (1.17, 1.66) <0.001
COPD, GOLD 2-4 + adjusted for childhood asthma 1.30 (1.09, 1.55) 0.003
Abbreviations: COPD chronic obstructive pulmonary disease; GOLD Global Initiative for Chronic Obstructive Lung Disease
aEach row represents a separate regression model, odds ratio (OR) and 95 % confidence interval (CI) for logistic regression
bCovariates for all analyses = age at enrollment in years + gender + race + pack years
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childhood asthma status (Additional file 1: Table S2).
Childhood pneumonia remained significantly associated
with COPD (OR 1.24; 95 % CI 1.03-1.50). Other signifi-
cant associations with childhood pneumonia were
maintained, with the exception of the association with
severe COPD exacerbations in the past year, which was
attenuated.
A corresponding analysis was run including only 723
subjects with childhood asthma (Additional file 1: Table
S3). In this subset, having childhood pneumonia showed
a stronger association with COPD than in the cohort
overall (OR 1.85; 95 % CI 1.10-3.18). The associations
with post-bronchodilator percent predicted FEV1 and
FVC remained significant. Other associations were no
longer significant.
To assess recall bias, the regression analysis was
repeated in a subset of 5,743 subjects who did not
report COPD or emphysema diagnosis at enrollment
(Additional file 1: Table S4). This included subjects
with undiagnosed COPD and without COPD. Al-
though prevalence of COPD was not significantly in-
creased in this subset, both percent predicted FEV1
and FVC remained significantly lower in subjects with
childhood pneumonia.Table 3 Respiratory Symptoms and Disease in Subjects With and W
Childhood Pneumoni
N = 854 (8.4 %)
Chronic bronchitis (%) 214 (25.1 %)
Number of COPD exacerbations in past year (SD) 0.65 (1.2)
Had a severe COPD exacerbation in past year (%) 140 (16.4 %)
Cardiovascular Disease (%)a 179 (21.0 %)
Diagnosed with asthma by healthcare provider (%)a 239 (28.0 %)
Childhood asthma (%)a 137 (16.0 %)
SGRQ Score, Total (SD)a 32.4 (24.0)
MMRC Dyspnea Scale, 0-4 (SD)a 1.6 (1.5)
Abbreviations: COPD chronic obstructive pulmonary disease; SD standard deviation;
Research Council
aSubjects included are fewer than total subjects due to subject survey response bei
bEach row represents a separate regression model
cOdds ratio (OR), 95 % confidence interval (CI) for logistic regression; beta coefficien
dCovariates for all analyses = age at enrollment in years + gender + race + pack-year
fAdditional covariates: ecurrent smoker; current smoker & FEV1 % predicted;
gFEV1 %Discussion
In adult smokers, a history of childhood pneumonia was
associated with COPD and reduced lung function, with
the greatest association in the subset of subjects with both
pneumonia and asthma in childhood. Those with child-
hood pneumonia had increased chronic bronchitis, more
frequent and severe COPD exacerbations, more CVD, in-
creased dyspnea, and worse disease-related quality of life.
There was a novel finding of greater airways disease
present in chest CT scans of subjects with childhood
pneumonia, supporting the idea that childhood disease is
associated with long term structural differences in the
lung and a distinct COPD phenotype. By comparison,
there was no difference in emphysema.
The role of childhood pneumonia in COPD develop-
ment has been investigated for over sixty years. Oswald
surveyed 1000 adults with chronic bronchitis in London
from 1951-53, finding 14.3 % reported childhood pneu-
monia compared to 6 % of controls [28]. In the 1970’s
Burrows proposed that childhood respiratory infections
are a risk factor for obstructive lung disease in adults,
with an enhanced effect in smokers, based on decreased
FEV1 and FEV1/FVC and increased chronic bronchitis in
415 subjects, mean age of 44.5, who reported childhood
respiratory trouble at < 16 years [3]. Four subsequentithout History of Childhood Pneumonia
a No Childhood Pneumonia Impact of Childhood Pneumoniab
N = 9302 (91.6 %) OR (95 % CI) or β (SE)c p Valued
1730 (18.6 %) 1.40 (1.18, 1.66) <0.001e
0.36 (0.9) 0.18 (0.03) <0.001f
1063 (11.4 %) 1.28 (1.04, 1.58) 0.02f
1455 (15.6 %) 1.20 (1.00-1.44) 0.047
1508 (16.3 %) 2.15 (1.83, 2.53) <0.001
586 (6.3 %) 3.30 (2.68, 4.05) <0.001
26.9 (22.8) 2.32 (0.67) <0.001g
1.3 (1.4) 0.12 (0.04) 0.006g
SGRQ St. George’s Respiratory Questionnaire; MMRC Modified Medical
ng missing or unclassifiable
t (β), standard error (SE) for linear regression
s
predicted
Fig. 1 Lung Function. Decreased lung function with history of childhood pneumonia. Post-bronchodilator spirometry values are shown.
Abbreviations: FEV1 = forced expiratory volume in the first second; FVC = forced vital capacity
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between childhood pneumonia in British subjects
born between 1911-1935 and adult lung function at
ages 34–74, each independently finding an association
with decreased FEV1 and FVC, and suggesting an as-
sociation between childhood pneumonia and COPD
[4–7]. Only one of these five studies used post-
bronchodilator data and none included COPD diagno-
sis in their outcomes [7].
The European Community Respiratory Health Survey
assessed pre-bronchodilator lung function in subjects
ages 20-44 in 1991-93 and then again 5-11 years later,
showing risk of developing COPD was doubled in sub-
jects with self-reported history of serious respiratory in-
fection at < 5 years, and that this factor accounted for
about 8 % of new cases [8, 9, 13]. Recent data from the
Tucson Children’s Respiratory Study provided longitu-
dinal post-bronchodilator lung function in 44 subjects
born between 1980-84 with radiographically diagnosed
pneumonia at ≤ 3 years, demonstrating an association
with a persistent decrease in post-bronchodilator FEV1
and FEV1/FVC up to age 26 [10].
Compared to prior investigations, our study examines
10,192 United States smokers ages 45-80, including 854Table 4 Effect of Childhood Pneumonia on Lung Function
Childhood Pneumonia No Chil
N = 850 (8.4 %) N = 924
FEV1 post-BD % predicted (SD) 69.1 % (25.7) 77.1 %
FVC post-BD % predicted (SD) 82.7 % (18.6) 87.4 %
FEV1/FVC post-BD (SD) 0.63 (0.17) 0.67 (0.
Abbreviations: FEV1 forced expiratory volume in the first second; FVC forced vital ca
aEach row represents a separate regression model, beta coefficient (β) and standard
bCovariate used for all analyses = pack yearscAdditional covariates = age at enrollmesubjects with childhood pneumonia. Our analysis sup-
ports the association between childhood pneumonia, re-
duced lung function in adulthood, and COPD. Our
study is unique due to the older age of participants, the
objective diagnosis of COPD by post-bronchodilator
spirometry, and chest CT analysis. Additionally, few
other studies have addressed this question in a popula-
tion of this size and included assessment of the com-
bined effect of pneumonia and childhood asthma.
Research into the association between childhood and
adult respiratory disease is complicated by the inherent
difficulty differentiating between diagnoses of childhood
pneumonia, asthma, and other respiratory illnesses,
which can overlap and evolve over time. Asthma is inde-
pendently associated with both childhood pneumonia
and adult COPD [10, 13, 29, 30]. More recent studies of
long-term outcomes from childhood pneumonia have
differentiated pneumonia from other respiratory illness
and have accounted for asthma in their analyses, finding
that the effect of childhood pneumonia on future lung
function is greater than that of other childhood respira-
tory infections, and is robust to adjustments for child-
hood asthma [5–8, 10]. This is similar to our finding,
where the association of childhood pneumonia withdhood Pneumonia Impact of Childhood Pneumoniaa
5 (91.6 %) β SE p Valueb
(25.4) −6.22 (0.88) <0.001
(18.3) −3.89 (0.65) <0.001
16) −0.02 (0.005) <0.001c
pacity; post-BD post bronchodilator
error (SE) for linear regression
nt + gender + race + height
Fig. 2 Chest CT. Airway changes on chest CT scans are associated with childhood pneumonia
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childhood asthmatics. Notably, we found that it was the
combined effect of pneumonia and asthma in childhood
had the greatest association with COPD.
Prior investigators have cited the possibility of im-
paired childhood lung growth and development playing
a role in this association [2, 4–6]. Chest CT changes
demonstrated in this analysis, with increased airways
disease in subjects with childhood pneumonia, support
this hypothesis. There are two potential explanations.
The first is that childhood pneumonia may cause airways
changes that increased risk for future disease. Alterna-
tively, there may be an underlying developmental abnor-
mality of the lung that increases risk for both childhood
pneumonia and lung disease in adult smokers. WhileTable 5 Effect of Childhood Pneumonia on Chest CT Parameters
Impact o
βc
Wall Area %, Segmental 0.46
Wall Area %, Subsegmentala 0.47
SRWA-Pi10 0.02
Emphysema % (-950 HU) 0.18
Gas Trapping %, expiratory scan (-856HU) 1.97
Total Lung Capacity (L) 0.001
Abbreviations: CT computed tomography; HU Hounsfield units; SRWA-Pi10 square ro
aData only available for a limited portion of the cohort
bEach row represents a separate regression model
cBeta coefficient (β) and standard error (SE) for linear regression
dCovariates used = age at enrollment in years + gender + race + pack-years + body masthma has also been associated with airways disease on
CT scans, the imaging associations in this analysis were
maintained even in a subset analysis where childhood
asthmatics were removed, suggesting that childhood
pneumonia likely has an independent role [31]. It would
be interesting to examine the extent of bronchiectasis in
this population given the known associations between
childhood pneumonia and bronchiectasis [32], however,
standardized visual readings of the chest CT scans are
not yet available in COPDGene.
Limitations
The ideal study for examining the connection between
childhood pneumonia and COPD would follow subjects
from conception to death [33]. However, the challengesf Childhood Pneumoniab
SE p Valued
(0.12) <0.001
(0.16) 0.003
(0.005) <0.001
(0.32) 0.57
(0.72) 0.006
(0.04) 0.99
ot wall area of a hypothetical airway with 10mm internal perimeter
ass index + CT scanner model
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proaches. Studies that use historical medical records
paired with current cohorts available for lung function
testing can be limited by selection bias [4–7]. Studies
that follow childhood cohorts are limited by younger age
at follow-up, especially given that the highest rates of
COPD are in those over 65 [7, 10, 34]. An alternative
method, employed by our study, was the collection of
self-reported medical history from a cohort of adults,
understanding that this does not include details such as
gestational age, birth weight, childhood socio-economic
status, and objective diagnostic tests for childhood pneu-
monia. This COPDGene Study assessment includes only
smokers; therefore we could not address the effect of
childhood pneumonia in non-smokers.
We acknowledge that our strategy may lead to poten-
tial recall bias, where adult subjects with respiratory dis-
ease may be more likely to recall childhood illness. This
analysis included a separate assessment for recall bias,
focusing only on subjects who did not report a known
COPD diagnosis, and thus were less likely to be biased
in recalling childhood respiratory problems. In this sub-
set analysis, childhood pneumonia remained associated
with reduced lung function. Therefore, it is unlikely that
overall study results were influenced by recall bias.
Childhood pneumonia was not associated with COPD in
this analysis, though this is not surprising given that the
subset includes nearly all those with normal lung func-
tion, while being most likely to remove subjects with
more severe COPD.
Self-reported pneumonia is a potential source of mis-
classification, however, prior studies have shown that
self-reported pneumonia diagnosis has relatively good
agreement with the medical record [35]. Additionally,
versions of the American Thoracic Society Question-
naire have previously been used to examine pneumonia
history, and prior epidemiologic surveys examining the
relationship have also used subject self-report [3, 9, 36, 37].
Random misclassification would be expected to bias to-
wards null results, yet we still found a significant
association.
Conclusions
We found that the combination of pneumonia in child-
hood and smoking in adulthood is associated with
COPD, increased respiratory symptoms, and reduced
lung function. This was supported by novel findings of
airways disease on chest CT scans. The greatest associ-
ation with COPD was seen in those who had both pneu-
monia and asthma in childhood. Further research will be
required to identify whether there are genetic associa-
tions that may play a role in determining a subtype of
COPD that originates with childhood respiratory disease.
In the meantime, medical providers have a valuableopportunity to reduce childhood pneumonias, especially
among asthmatics, and to counsel patients about the in-
creased risk from smoke exposure in those who have
had pneumonia during childhood.
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